Foghorn Therapeutics (FHTX) Enterprise Value (2019 - 2026)

Foghorn Therapeutics' Enterprise Value history runs 8 years deep, the most recent figure standing at -$88.9 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 45.7% year-over-year to -$88.9 million; the TTM figure through Mar 2026 stood at -$88.9 million (down 45.7% YoY), while the FY2025 annual figure was -$82.1 million, down 48.1% from the prior year.
• Enterprise Value was -$88.9 million for Q1 2026 at Foghorn Therapeutics, down from -$82.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$50.6 million in Q1 2023 to a low of -$213.6 million in Q1 2022.
• Historically, Enterprise Value has averaged -$82.4 million across 5 years, with a median of -$73.8 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value plunged 221.52% in 2022, then jumped 76.3% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$52.2 million in 2022, then tumbled by 53.86% to -$80.3 million in 2023, then surged by 30.97% to -$55.5 million in 2024, then plunged by 48.1% to -$82.1 million in 2025, then dropped by 8.26% to -$88.9 million in 2026.
• The last three Enterprise Value figures came in at -$88.9 million (Q1 2026), -$82.1 million (Q4 2025), and -$90.6 million (Q3 2025), per Business Quant data.